An Optimized Decision Support Model for COVID-19 Diagnostics Based on Complex Fuzzy Hypersoft Mapping

COVID-19 has shaken the entire world economy and affected millions of people in a brief period. COVID-19 has numerous overlapping symptoms with other upper respiratory conditions, making it hard for diagnosticians to diagnose correctly. Several mathematical models have been presented for its diagnosis and treatment. This article delivers a mathematical framework based on a novel agile fuzzy-like arrangement, namely, the complex fuzzy hypersoft (CFHS) set, which is a formation of the complex fuzzy (CF) set and the hypersoft set (an extension of soft set). First, the elementary theory of CFHS is developed, which considers the amplitude term (A-term) and the phase term (P-term) of the complex numbers simultaneously to tackle uncertainty, ambivalence, and mediocrity of data. In two components, this new fuzzy-like hybrid theory is versatile. First, it provides access to a broad spectrum of membership function values by broadening them to the unit circle on an Argand plane and incorporating an additional term, the P-term, to accommodate the data's periodic nature. Second, it categorizes the distinct attribute into corresponding sub-valued sets for better understanding. The CFHS set and CFHS-mapping with its inverse mapping (INM) can manage such issues. Our proposed framework is validated by a study establishing a link between COVID-19 symptoms and medicines. For the COVID-19 types, a table is constructed relying on the fuzzy interval of [0,1]. The computation is based on CFHS-mapping, which identifies the disease and selects the optimum medication correctly. Furthermore, a generalized CFHS-mapping is provided, which can help a specialist extract the patient's health record and predict how long it will take to overcome the infection.

A Case of Guillain-Barré Syndrome Associated With COVID-19.

A novel member of human RNA coronavirus, which is an enveloped betacoronavirus, has been termed severe acute respiratory syndrome coronavirus-2 (SARS COV-2). The illness caused by SARS COV-2 is referred to as the coronavirus disease 2019 (COVID-19). It is a highly contagious disease that has resulted in a global pandemic. The clinical spectrum of COVID-19 ranges from asymptomatic illness to acute respiratory distress syndrome, septic shock, multi-organ dysfunction, and death. The most common symptoms include fever, fatigue, dry cough, dyspnea, and diarrhea. Neurological manifestations have also been reported. However, the data on the association of Guillain-Barré syndrome (GBS) with COVID-19 are scarce. We report a rare case of a COVID-19-positive 36-year-old immunocompromised male who presented with clinical features of GBS. His clinical examination showed generalized weakness and hyporeflexia. The cerebrospinal fluid (CSF) analysis showed albuminocytological dissociation. Intravenous immunoglobulin (IVIG) was administered based on the high clinical suspicion of GBS. The patient's neurological condition worsened with progression to bulbar weakness and ultimately neuromuscular respiratory failure requiring mechanical ventilation. His nerve conduction studies were consistent with demyelinating polyneuropathy. He received five plasma exchange treatments and was successfully weaned from mechanical ventilation. A brain and cervical spine magnetic resonance imaging was obtained to rule out other causes, which was normal. COVID-19 is believed to cause a dysregulated immune system, which likely plays an important role in the neuropathogenesis of GBS.

A Case of Extracorporeal Membrane Oxygenation as a Salvage Therapy for COVID-19-Associated Severe Acute Respiratory Distress Syndrome: Mounting Evidence.

Coronavirus disease 2019 (COVID-19) caused by a novel human coronavirus has led to a tsunami of viral illness across the globe, originating from Wuhan, China. Although the value and effectiveness of extracorporeal membrane oxygenation (ECMO) in severe respiratory illness from COVID-19 remains unclear at this time, there is emerging evidence suggesting that it could be utilized as an ultimate treatment in appropriately selected patients not responding to conventional care. We present a case of a 32-year-old COVID-19 positive male with a history of diabetes mellitus who was intubated for severe acute respiratory distress syndrome (ARDS). The patient's hypoxemia failed to improve despite positive pressure ventilation, prone positioning, and use of neuromuscular blockade for ventilator asynchrony. He was evaluated by a multidisciplinary team for considering ECMO for refractory ARDS. He was initiated on venovenous ECMO via dual-site cannulation performed at the bedside. Although his ECMO course was complicated by bleeding, he showed a remarkable improvement in his lung function. ECMO was successfully decannulated after 17 days of initiation. The patient was discharged home after 47 days of hospitalization without any supplemental oxygen and was able to undergo active physical rehabilitation. A multidisciplinary approach is imperative in the initiation and management of ECMO in COVID-19 patients with severe ARDS. While ECMO is labor-intensive, using it in the right phenotype and in specialized centers may lead to positive results. Patients who are young, with fewer comorbidities and single organ dysfunction portray a better prognosis for patients in which ECMO is utilized.